Jane Street Group LLC Has $3.42 Million Stake in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Jane Street Group LLC boosted its position in ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) by 119.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 222,307 shares of the company's stock after purchasing an additional 121,083 shares during the period. Jane Street Group LLC owned about 0.81% of ClearPoint Neuro worth $3,419,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Barclays PLC raised its holdings in ClearPoint Neuro by 24.3% in the 3rd quarter. Barclays PLC now owns 5,674 shares of the company's stock valued at $64,000 after acquiring an additional 1,109 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of ClearPoint Neuro by 58.7% during the third quarter. JPMorgan Chase & Co. now owns 9,770 shares of the company's stock worth $110,000 after purchasing an additional 3,612 shares during the period. Conway Capital Management Inc. increased its holdings in shares of ClearPoint Neuro by 13.9% during the fourth quarter. Conway Capital Management Inc. now owns 161,225 shares of the company's stock worth $2,480,000 after purchasing an additional 19,725 shares during the period. Parsons Capital Management Inc. RI increased its holdings in shares of ClearPoint Neuro by 1.9% during the fourth quarter. Parsons Capital Management Inc. RI now owns 141,573 shares of the company's stock worth $2,177,000 after purchasing an additional 2,600 shares during the period. Finally, R Squared Ltd bought a new position in shares of ClearPoint Neuro during the fourth quarter worth approximately $32,000. 30.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Lake Street Capital raised their target price on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the stock a "buy" rating in a report on Tuesday, January 21st. Stifel Nicolaus lifted their price objective on shares of ClearPoint Neuro from $19.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, April 1st. Finally, B. Riley lifted their price objective on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th.

ClearPoint Neuro Price Performance

NASDAQ:CLPT traded up $0.26 during mid-day trading on Friday, reaching $13.18. The stock had a trading volume of 333,088 shares, compared to its average volume of 235,465. The stock has a 50-day simple moving average of $12.87 and a two-hundred day simple moving average of $14.24. The stock has a market capitalization of $368.90 million, a PE ratio of -19.10 and a beta of 1.03. ClearPoint Neuro, Inc. has a 12 month low of $5.11 and a 12 month high of $19.22.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.07). The business had revenue of $8.49 million for the quarter, compared to analyst estimates of $8.21 million. ClearPoint Neuro had a negative return on equity of 62.10% and a negative net margin of 59.64%. Equities analysts expect that ClearPoint Neuro, Inc. will post -0.66 EPS for the current year.

ClearPoint Neuro Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.